Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients

BACKGROUND: Programmed cell death-1 (PD-1) inhibitor was proven to be useful for the recurrent/metastatic head and neck squamous carcinoma (R/M HNSCC) patients. Though both PD-1 inhibitor alone and combination with chemotherapy showed some benefit for PFS and OS, the survival outcome was still not s...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lu, Chen, Lu, Yan, Lu, Guo, Yueqian, Li, Fang, Fan, Ming, Lan, Mei, Lai, Xin, Zhou, Jie, Huang, Yecai, Xu, Peng, Lang, Jinyi, Feng, Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318764/
https://www.ncbi.nlm.nih.gov/pubmed/37403098
http://dx.doi.org/10.1186/s13014-023-02310-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10318764/
https://www.ncbi.nlm.nih.gov/pubmed/37403098
http://dx.doi.org/10.1186/s13014-023-02310-8

Ejemplares similares